Alkermes Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Balanced Scorecard
This Alkermes Balanced Scorecard Analysis gives you a clear, company-specific view of financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual report content, so you can see exactly what you're getting before buying. Purchase the full version for the complete ready-to-use analysis.
Benefits
Pipeline Discipline
Pipeline discipline matters at Alkermes because CNS programs often take 7-10 years and face high Phase 2 and Phase 3 attrition. A Balanced Scorecard ties discovery, Phase 2, Phase 3, and FDA filing gates to one plan, so teams do not chase isolated wins. That matters in FY2025, when every late-stage decision can protect capital and focus R&D on the few assets most likely to reach patients.
Launch Tracking
In FY2025, Alkermes had 4 marketed medicines: LYBALVI, ARISTADA, ARISTADA INITIO, and VIVITROL. Launch tracking should watch monthly prescription growth, payer access, refill rates, and discontinuation, because those metrics show whether uptake is sticking. In schizophrenia and bipolar I disorder, steady refill behavior and low stop rates matter more than one-time scripts; they help turn a launch into a durable CNS franchise.
Capital Allocation
Capital allocation is a clear strength for Alkermes: in fiscal 2025, the company can weigh R&D spending against commercial returns using R&D intensity, gross margin, and operating cash flow together. That matters because its revenue base from LYBALVI and VIVITROL helps fund pipeline bets while protecting cash discipline. A scorecard view makes it easier to back the highest-probability programs and cut weaker ones fast.
Patient Proof
Patient proof is a strong fit for Alkermes because its core markets still have major unmet need: schizophrenia affects about 24 million people worldwide, bipolar I disorder about 40 million people with bipolar disorder overall, and multiple sclerosis about 2.8 million people globally. In CNS therapy, scorecard measures can link symptom control, daily functioning, and treatment persistence to business results. That matters for Alkermes because steady persistence helps protect revenue and supports long-term growth in products such as VIVITROL and LYBALVI.
Cross-Functional Alignment
Cross-functional alignment matters because biopharma work moves through clinical, regulatory, manufacturing, and commercial teams at once. A shared scorecard lets Alkermes spot enrollment slips, supply bottlenecks, or access gaps early, so one team's delay does not become a company-wide miss.
That matters in a business where one delayed trial site, one rejected lot, or one slow payer decision can push milestones by months. With one view of the key metrics, Alkermes can cut siloed calls, speed fixes, and keep execution tighter across the full product cycle.
Balanced Scorecard Sharpens Alkermes Capital Discipline
For Alkermes, the main benefit of a Balanced Scorecard is tighter capital use: in FY2025 it can link 4 marketed medicines, R&D gates, and cash flow to one plan. That helps protect launch momentum, catch access or supply issues early, and keep CNS programs focused on the few bets most likely to reach patients.
| FY2025 benefit | Why it matters |
|---|---|
| 4 marketed medicines | Funds pipeline discipline |
| Launch metrics | Shows real uptake |
| Shared scorecard | Speeds cross-team fixes |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Slow Readouts
Slow readouts are a real issue for Alkermes because CNS trials often need 24 to 60 months to reach a clear Phase 2 or Phase 3 decision, so scorecard metrics can lag the business. That means 2025 updates may show little change even when the team is still spending heavily on development and de-risking the pipeline. For investors, this lowers the scorecard's speed as a decision tool and makes it less useful for fast reallocations.
Metric Noise
Metric noise is a real drawback for Alkermes because FDA feedback, payer coverage, and competitor launches can move results more than day-to-day execution. In 2025, that meant scorecard swings could reflect a reimbursement change or a rival launch, not a real shift in management skill. So a higher or lower score may mix internal performance with outside shocks, which makes the read less clean.
Data Burden
A credible scorecard for Alkermes has to reconcile trial, manufacturing, and sales data before each metric is trusted. In 2025, that kind of control means extra validation work across a regulated chain, and it can slow decisions.
The cost is real: more manual checks, more delay, and more staff time spent fixing data rather than acting on it. If the inputs are late or messy, the scorecard can misstate pipeline, output, or launch performance.
Concentration Risk
In FY2025, Alkermes still relied on a small set of commercial products, so a setback in one franchise can skew the whole scorecard. If a product like VIVITROL or LYBALVI misses demand, pricing, or supply targets, the dashboard can look weaker than the rest of the business. That makes the Balanced Scorecard fragile, because one issue can overstate both risk and strength.
Outcome Complexity
Outcome complexity makes Alkermes Balanced Scorecard metrics noisy, because patient improvement, adherence, and relapse prevention rarely move together in one clean KPI. In CNS care, one endpoint can miss differences across depression, schizophrenia, and alcohol use disorder, plus inpatient versus outpatient settings. That can hide real value, since a 5% swing in discontinuation or relapse can matter more than a flat average score.
Alkermes' 2025 Scorecard: Slow Trial Readouts, Big Single-Brand Risk
Alkermes' scorecard drawbacks are mainly timing and noise: CNS trials can take 24 to 60 months, so FY2025 metrics may lag real business shifts. Reimbursement, FDA feedback, and rival launches can move the score more than execution. With a small product base, one miss in VIVITROL or LYBALVI can skew the whole view.
| Issue | 2025 signal |
|---|---|
| Slow readouts | 24-60 months |
| Portfolio concentration | 1-2 key brands |
Preview the Actual Deliverable
Alkermes Reference Sources
This is the actual Alkermes Balanced Scorecard analysis document you'll receive after purchase – no sample content, just the full report. The preview shown here is taken directly from the final file, so what you see is what you get. Once purchased, the complete, detailed version is unlocked immediately for download.
Frequently Asked Questions
It measures whether Alkermes is turning CNS science into durable clinical and commercial progress. The most useful indicators are Phase 2 and Phase 3 advancement, NDA or label-expansion milestones, and launch metrics such as prescription growth, payer coverage, and discontinuation rates. Those signals are more revealing than any single quarter of revenue or EPS for a development-heavy biopharma company.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.